https://nl.marketscreener.com/koers/aandeel/TME-PHARMA-N-V-31472058/nieuws/Tme-Pharma-N-V-kondigt-NOX-A12-combinatieregime-met-Bevacizumab-aan-Overlevingskans-van-17-maanden-44830703/?utm_source=telegram&utm_medium=social&utm_campaign=share